Xenon Pharmaceuticals financials
$37.25+1.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $0.00 | $0.00 | $9.4M | $18.4M | $32.2M | $6.8M | — | $311.0K | $1.8M |
| Gross profit | $7.5M | $0.00 | $0.00 | $9.4M | $18.4M | $32.2M | $6.8M | — | $311.0K | $1.8M |
| Gross margin | 100.0% | — | — | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% |
| Operating income | -$373.1M | -$279.3M | -$214.1M | -$129.1M | -$79.0M | -$31.3M | -$42.8M | -$38.0M | -$32.6M | -$24.8M |
| Net income | -$345.9M | -$234.3M | -$182.4M | -$124.9M | -$77.1M | -$28.0M | -$40.0M | -$31.6M | -$30.7M | -$23.0M |
| Net margin | −4612.1% | — | — | −1324.3% | −418.1% | −87.1% | −586.1% | — | −9872.7% | −1275.5% |
| Diluted EPS | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | $-1.54 | $-1.63 | $-1.72 | $-1.48 |
| EBITDA | -$370.5M | -$276.7M | -$212.0M | -$127.7M | -$78.1M | -$30.7M | -$42.4M | -$37.5M | -$31.9M | -$24.0M |
| Operating cash flow | -$279.1M | -$181.4M | -$151.1M | -$101.0M | -$69.5M | -$48.1M | -$4.7M | -$34.7M | -$28.7M | -$19.6M |
| Free cash flow | -$279.9M | -$184.5M | -$156.7M | -$103.9M | -$71.6M | -$50.8M | -$6.0M | -$35.2M | -$29.0M | -$19.8M |
| Diluted shares | 79.3M | 77.9M | 66.9M | 60.5M | 43.6M | 34.5M | 25.9M | 19.4M | 18.0M | 15.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $199.2M | $142.7M | $148.6M | $57.2M | $175.7M | $175.7M |
| Short-term investments | $349.7M | $484.2M | $489.4M | $534.8M | $376.1M | $376.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $7.7M | $0.00 |
| Total assets | $633.2M | $798.1M | $964.8M | $754.1M | $572.0M | $572.0M |
| Total liabilities | $51.4M | $43.2M | $36.9M | $32.6M | $22.0M | $22.0M |
| Shareholders' equity | $581.8M | $754.9M | $927.9M | $721.5M | $550.0M | $550.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology